ASH 2022 | Independent prognostic value of total metabolic tumor volume in advanced-stage FL
Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, presents results from the FOLL12 study (NCT02063685) assessing the use of total metabolic tumor volume (TMTV) as a prognostic factor in treatment naïve advanced-stage follicular lymphoma (FL). Pre-treatment TMTV and high-risk FLIPI-2 were strong independent predictors of progression-free survival (PFS), and Dr Luminari suggests that the combination of TMTV and FLIPI-2 may improve risk stratification and risk-adapted therapy in FL. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
